The End of Quarterly Earnings? What the SEC’s Reporting Overhaul Means for Small Caps

A regulatory change decades in the making may finally be approaching — and for small and microcap public companies, the implications could be significant.

The Securities and Exchange Commission is preparing a proposal that would make quarterly earnings reporting optional, allowing public companies to instead report financial results twice per year. The proposal, which could be published as early as April, is currently in discussions between the SEC and major stock exchanges regarding how listing rules would need to adjust. Once published, it will enter a public comment period of at least 30 days before the SEC votes on the rule.

SEC Chairman Paul Atkins and President Donald Trump have both voiced support for the shift. Trump first raised the idea during his first term in 2018, arguing that semiannual reporting would reduce short-term thinking and cut the administrative costs burdening public companies. That argument has only gained traction since. The quarterly treadmill — preparing financial statements, coordinating with auditors, hosting earnings calls — runs on a near-constant cycle for CFOs at small public companies, consuming resources that lean teams at microcap firms can ill afford.

For larger companies with dedicated investor relations departments and deep finance teams, quarterly reporting is manageable. For a $200 million market cap company with 50 employees, it can feel like a full-time job. Supporters of the proposed change argue this compliance burden is one of the key reasons why many companies choose to stay private longer — or simply never go public at all. A semiannual reporting structure could lower the bar to entry for the public markets and broaden the investable universe of small and microcap stocks.

The EU and the UK both moved to semiannual mandatory reporting roughly a decade ago. Notably, many companies in both markets continued reporting quarterly by choice — suggesting the market itself can enforce disclosure standards even without a regulatory mandate. That precedent is likely to be a central argument for U.S. adoption.

The opposition is real, however. Critics argue that less frequent disclosures reduce market transparency, create wider informational gaps between company insiders and retail investors, and could increase volatility around the two annual reporting windows. For microcap stocks — where information asymmetry is already higher and trading volumes are lower — a six-month gap between financial updates raises legitimate concerns about price discovery.

There’s also the question of what “optional” really means in practice. Institutional investors and analysts who cover microcap names expect regular data. Companies that choose semiannual reporting may find themselves at a disadvantage in terms of analyst coverage and institutional interest, particularly if peers in the same sector continue reporting quarterly. In other words, the market may continue enforcing the quarterly standard even if the SEC doesn’t.

What’s clear is that this proposal has direct implications for the small and microcap space — more so than for any other segment of the public markets. The cost-benefit calculation is most acute at smaller companies, and the potential to attract more issuers to the public markets is a legitimate upside worth monitoring.

The SEC’s formal proposal is expected to follow soon. For issuers, investors, and advisors in the small and microcap space, the comment period will be the time to shape what this change actually looks like in practice.

Biden’s Scrutiny of Private Equity Healthcare Deals: A New Hurdle for Investors?

The healthcare industry has long been a fertile ground for private equity investments, with firms eagerly scooping up stakes in hospitals, physician practices, and ancillary service providers. However, a recent move by the Biden administration to scrutinize these deals more closely could signal turbulent times ahead for investors eyeing opportunities in the healthcare space.

In February 2024, the White House announced plans to establish an interagency taskforce dedicated to investigating the effects of private equity ownership on healthcare costs, quality, and workforce compensation. This move comes amid growing concerns from lawmakers and advocacy groups about the potential negative impacts of private equity firms’ profit-driven strategies on patient care and healthcare affordability.

The taskforce’s mandate is broad, encompassing a comprehensive examination of how private equity business models influence everything from staffing levels and worker wages to service availability and pricing dynamics across various healthcare sectors. While the specific policy implications remain uncertain, the heightened scrutiny alone could cast a cloud of uncertainty over future private equity healthcare deals, particularly smaller acquisitions of physician practices, nursing homes, and ancillary service providers.

For investors, this development represents a potential new hurdle in an already challenging regulatory landscape. Private equity firms have long been drawn to the healthcare sector due to its recession-resistant nature, steady cash flows, and the potential for operational improvements and consolidation plays. However, the increased regulatory oversight could make it more difficult for these firms to execute their traditional playbook of cost-cutting, leveraged buyouts, and aggressive growth strategies. Nathan Cali, Head of Healthcare Investment Banking at Noble Capital Markets said, “Certainly, government oversight never means more business to be done, and alternatively may result in fewer healthcare services, healthcare innovations and reduce opportunities for patients. Private equity typically fuels great innovation with the necessary growth funds to already thriving good businesses. Government regulations and oversight may reduce these types of activities.”

One area likely to face heightened scrutiny is the acquisition of physician practices by private equity firms. These deals have been a contentious issue, with critics arguing that private equity ownership can lead to higher healthcare costs, a focus on profitable procedures over patient needs, and potential conflicts of interest. If the taskforce recommends additional regulations or restrictions on such acquisitions, it could dampen private equity firms’ appetite for these investments, potentially limiting exit opportunities for investors.

Similarly, private equity ownership of nursing homes and long-term care facilities has been a subject of intense debate, with concerns over staffing levels, quality of care, and the diversion of resources towards profit maximization. Increased oversight in this sector could lead to stricter requirements for private equity firms, potentially impacting their ability to implement cost-cutting measures and limiting the financial returns on these investments.

Beyond the direct impact on private equity firms, the taskforce’s findings and recommendations could also have broader implications for the healthcare sector as a whole. If the investigation uncovers evidence of harmful practices or negative outcomes associated with private equity ownership, it could prompt lawmakers to pursue more comprehensive regulatory changes or industry-wide reforms.

Such changes could include enhanced transparency requirements, stricter oversight of billing practices, or even limitations on the types of healthcare entities that can be acquired by private equity firms. These measures could potentially level the playing field between private equity-owned and non-profit healthcare providers, but could also create additional compliance burdens and operational challenges for all industry participants.

For investors, navigating this shifting landscape will require a keen eye for regulatory risks and a deep understanding of the potential impacts on specific healthcare subsectors. While the taskforce’s ultimate recommendations remain uncertain, investors should be prepared for potential changes in valuations, deal structures, and exit strategies for private equity healthcare investments.

Noble Capital Markets’ Senior Research Analyst Robert Leboyer states, “The Administration’s provisions for Medicare price negotiations in the Inflation Reduction Act have added uncertainty to a high-risk business, causing reduction in the value of future drugs and discontinuation of some drugs in development. Small company valuations were reduced and many were unable to raise capital. Additional regulation for healthcare facilities would add administrative costs and reduce profitability, reducing the incentives and competition in providing the best care for patients.”

Additionally, investors may need to reassess their due diligence processes to scrutinize not only the financial and operational aspects of potential investments but also the potential regulatory and reputational risks associated with private equity ownership in the healthcare space.

Despite the challenges, the healthcare sector remains an attractive target for private equity firms due to its resilience, growth potential, and the ongoing need for operational efficiencies and consolidation. However, the Biden administration’s heightened scrutiny serves as a reminder that the pursuit of profits must be balanced against the broader societal impact and responsibilities inherent in the healthcare industry.

As the taskforce’s work unfolds, investors would be wise to closely monitor developments and adapt their strategies accordingly. Those who can navigate this new reality adeptly may find themselves well-positioned to capitalize on the enduring opportunities in the healthcare sector, while those who fail to adjust could face significant headwinds in a rapidly evolving regulatory and political landscape.